We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Clorox Company (CLX - Free Report) reported second-quarter fiscal 2017 results, wherein adjusted earnings from continuing operations of $1.25 per share rose 9.6% year over year and also beat the Zacks Consensus Estimate of $1.14.
The company now expects earnings for fiscal 2017 to be in the range of $5.23–$5.38 per share in comparison to previous estimate of $5.23–$5.43 per share. The company’s recent guidance includes 5 cent decrease in anticipated benefit from adopting Accounting Standards Update (ASU) 2016-09.
Earnings Estimate Revision: The Zacks Consensus Estimate has been trending down going into the earnings release. If we look at Clorox’s performance in the trailing four quarters (excluding the quarter under review), the company has outperformed the Zacks Consensus Estimate by an average of 3.2%.
Clorox Company (The) Price, Consensus and EPS Surprise
Revenues: Clorox generated net sales of $1,406 million that climbed 4.5% year over year, marginally surpassing the Zacks Consensus Estimate of $1,405 million. The increase was backed by solid volume growth, contributions from the RenewLife business and improved prices in the International division, marginally offset by unfavorable mix and currency headwinds. On a currency-adjusted basis, sales were up 6%.
The company now anticipates sales growth of 3%–4% for fiscal 2017, up from the previous guidance of 2% to 4%. The company continues to anticipate currency-neutral sales growth expected in the range of 4%–6%. Sales in fiscal 2017 are expected to gain from its RenewLife acquisition, partially offset by currency headwinds.
Check back later for our full write up on Clorox’s earnings report!
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 """"Strong Buy"""" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 """"Strong Sells"""" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Clorox (CLX) Beats Q2 Earnings & Revenues, Updates View
The Clorox Company (CLX - Free Report) reported second-quarter fiscal 2017 results, wherein adjusted earnings from continuing operations of $1.25 per share rose 9.6% year over year and also beat the Zacks Consensus Estimate of $1.14.
The company now expects earnings for fiscal 2017 to be in the range of $5.23–$5.38 per share in comparison to previous estimate of $5.23–$5.43 per share. The company’s recent guidance includes 5 cent decrease in anticipated benefit from adopting Accounting Standards Update (ASU) 2016-09.
Earnings Estimate Revision: The Zacks Consensus Estimate has been trending down going into the earnings release. If we look at Clorox’s performance in the trailing four quarters (excluding the quarter under review), the company has outperformed the Zacks Consensus Estimate by an average of 3.2%.
Clorox Company (The) Price, Consensus and EPS Surprise
Clorox Company (The) Price, Consensus and EPS Surprise | Clorox Company (The) Quote
Revenues: Clorox generated net sales of $1,406 million that climbed 4.5% year over year, marginally surpassing the Zacks Consensus Estimate of $1,405 million. The increase was backed by solid volume growth, contributions from the RenewLife business and improved prices in the International division, marginally offset by unfavorable mix and currency headwinds. On a currency-adjusted basis, sales were up 6%.
The company now anticipates sales growth of 3%–4% for fiscal 2017, up from the previous guidance of 2% to 4%. The company continues to anticipate currency-neutral sales growth expected in the range of 4%–6%. Sales in fiscal 2017 are expected to gain from its RenewLife acquisition, partially offset by currency headwinds.
Zacks Rank: Currently, Clorox carries a Zacks Rank #3 (Hold) which is subject to change following the earnings announcement. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on Clorox’s earnings report!
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 """"Strong Buy"""" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 """"Strong Sells"""" and other private research. See these stocks free >>